A Delaware federal jury has determined a Japanese pharmaceutical company owes a Massachusetts-based drug developer more than $115 million for patent infringement.

The verdict, reached Friday, is a win for the team of Latham & Watkins and Finnegan attorneys representing counterclaimant Sarepta Therapeutics in the patent suit that's been ongoing for more than three years.